KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires $37,812.18 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 4,137 shares of the stock in a transaction dated Monday, February 10th. The stock was acquired at an average cost of $9.14 per share, with a total value of $37,812.18. Following the transaction, the insider now owns 5,090,582 shares of the company’s stock, valued at approximately $46,527,919.48. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 7th, Venrock Healthcare Capital Par bought 73,649 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par purchased 14,562 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The shares were bought at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Trading Up 0.9 %

NASDAQ:KALV opened at $9.27 on Wednesday. The firm’s fifty day simple moving average is $8.75 and its 200 day simple moving average is $10.58. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $16.88. The firm has a market capitalization of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. On average, analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Bank of America started coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its stake in shares of KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares during the period. SG Americas Securities LLC acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $153,000. China Universal Asset Management Co. Ltd. grew its holdings in KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,328 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in KalVista Pharmaceuticals by 23.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after buying an additional 121,615 shares during the period. Finally, Emerald Advisers LLC lifted its holdings in KalVista Pharmaceuticals by 29.8% in the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after buying an additional 192,091 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).